Compare FICO & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FICO | VANI |
|---|---|---|
| Founded | 1956 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.3B | 119.0M |
| IPO Year | 1995 | 2014 |
| Metric | FICO | VANI |
|---|---|---|
| Price | $995.54 | $1.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 1 |
| Target Price | ★ $1,689.92 | $3.50 |
| AVG Volume (30 Days) | ★ 337.6K | 231.2K |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.78 | N/A |
| EPS | ★ 28.12 | N/A |
| Revenue | ★ $1,032,475,000.00 | $4,000,000.00 |
| Revenue This Year | $27.28 | N/A |
| Revenue Next Year | $16.97 | N/A |
| P/E Ratio | $34.26 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $870.01 | $0.92 |
| 52 Week High | $1,998.01 | $1.92 |
| Indicator | FICO | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 34.48 | 40.80 |
| Support Level | $889.51 | $1.26 |
| Resistance Level | $1,117.39 | $1.55 |
| Average True Range (ATR) | 41.88 | 0.08 |
| MACD | -18.43 | -0.02 |
| Stochastic Oscillator | 24.79 | 3.74 |
Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's US-centric credit scores business accounts for most of the firm's revenue and profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.